ClinicalTrials.gg

Program

V181

A development code. Also written as “V181 High-Potency Level”, “V181 Mid-Potency Level” and “V181 Low-Potency Level”.

Its studies are mostly in Dengue, led by Merck.

Furthest: phase 3, since Jun 2, 20252 company-led studies, 1 open or runningNext primary completion: Sep 6, 2031 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merck21 open or runningphase 3since Jun 2, 2025Aug 17, 2022Sep 6, 2031phase 3 · NCT07013487
  • Named in Merck’s own pipeline as V181, phase 3, as of Nov 2, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 17, 2022First study: phase 2 study in Dengue DiseaseFirst studyNCT05507450 · 1,271 enrolled · United States, Australia, Canada and more
  2. Jun 2, 2025Phase 3 study in HealthyNCT07013487 · 12,000 enrolled · Indonesia, Malaysia, Philippines and more

Ahead

  1. Sep 6, 2031Primary completion: phase 3 study in HealthyNCT07013487

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“The primary objective of this study is to compare the dengue virus-neutralizing antibody geometric mean titers (GMTs) for each of the 4 dengue serotypes (DENV1, DENV2, DENV3, and DENV4) at Day 28 post-vaccination for participants administered the V181 Low-Potency Level vaccine versus the V181 Mid…”study summary, read by Claude · the study

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07013487Healthy · Indonesia, Malaysia, Philippines and more3Active, not recruitingSep 6, 203112,000
NCT05507450Dengue Disease · United States, Australia, Canada and more2CompletedJun 5, 20231,271

How it is read

Names in the registry

  • “V181”, 1 entry
  • “V181 High-Potency Level”, 1 entry
  • “V181 Mid-Potency Level”, 1 entry
  • “V181 Low-Potency Level”, 1 entry

Codes read as this program: V181.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.